There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - Senate

Short Titles as Introduced

PRICED Act
Price Relief, Innovation, and Competition for Essential Drugs Act

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 7 years.


Actions Overview (1)

Date Actions Overview
06/23/2016Introduced in Senate

All Actions (1)

Date All Actions
06/23/2016Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Action By: Senate

Cosponsors (1)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. McCain, John [R-AZ]* 06/23/2016

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
Senate Health, Education, Labor, and Pensions06/23/2016 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Subjects (4)


Latest Summary (1)

There is one summary for S.3094. View summaries

Shown Here:
Introduced in Senate (06/23/2016)

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.